Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for researchers and research institutions seeking to conduct substance use research using existing datasets and secondary data analysis. Eligible applicants typically include academic medical centers, university research departments, independent research institutes, and other 501(c)(3) research organizations. The R21 mechanism specifically supports exploratory/developmental research projects designed to generate preliminary data for future grant applications. This grant does NOT support new clinical trial research—only observational studies, retrospective analyses, and secondary data analyses are allowed. The research must focus on substance use (including alcohol, tobacco, and illicit drugs) prevention, treatment, or policy. There are no geographic restrictions; researchers may be located anywhere in the United States or eligible foreign institutions. The NIH requires investigators to have appropriate credentials (typically PhD, MD, or equivalent) and institutional affiliation with grant management capacity.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- Colleges (all higher ed)
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Researcher (independent)
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
How to apply
Application links
Required documents
- NIH Form SF-424 (R&R) (Application for Federal Assistance for Research & Related Activities)
- Project Narrative (Research Strategy section: Significance, Innovation, Approach; typically 6–8 pages including figures/tables)
- Specific Aims (1 page maximum)
- Biographical Sketch for PI and all key personnel (NIH Biosketch format, 5 pages each)
- Budget and Budget Justification (simplified budget for R21; typically $75,000–$225,000 total costs)
- Facilities and Administrative (F&A) cost allocation documentation
- Data Access Plan (demonstrating access to the existing dataset and any data use agreements)
- Letters of Support/Institutional Endorsement from collaborating organizations if applicable
- IRB approval letter or exemption determination (if human subjects research)
- Conflict of Interest disclosures
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.273 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$125,900,663
-
$34,675,742
-
$34,469,501
-
$33,261,336
-
$32,897,567
-
$31,652,514
-
$30,394,602
-
$29,223,384
-
$29,195,978
-
$29,168,993
Top States by Funding
- CA 15 awards $242.3M
- NY 3 awards $162.6M
- OR 7 awards $96.3M
- NC 4 awards $67.1M
- IN 3 awards $57.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.273). How funding has trended year over year.
| 2024 | $430,377,419 | |
| 2025 | $429,906,735 | |
| 2026 est. | $12,401,560 |
FAQ
Who can apply for this R21 grant?
Early-stage researchers, established investigators exploring a new research direction, and research teams at academic institutions, hospitals, and nonprofit research organizations with 501(c)(3) status or institutional NIH grants management infrastructure. Principal Investigators must typically have a doctoral degree (PhD, MD, DO, DVM, or equivalent).
What is the difference between this R21 and other NIH research grants?
The R21 is designed for exploratory/developmental research intended to generate pilot data and feasibility findings. It has a shorter project period (typically 2 years) and lower budget cap (~$225,000 total costs) than R01 grants. Clinical trials are not allowed—this grant requires secondary analysis of existing data only.
When are the application deadlines?
Standard NIH deadlines typically occur three times annually (February, June, and October). The specific deadline listed is December 3, 2027. Check NIH's grants.gov portal for exact upcoming deadlines.
What kinds of substance use research are supported?
Studies examining prevention, treatment, recovery, policy, epidemiology, health disparities, and implementation science related to alcohol, tobacco, opioids, cannabis, and other drugs. Using existing datasets (national surveys, electronic health records, claims data, etc.) is encouraged.
How competitive is this funding?
R21 grants are moderately competitive. Success rates for NIH R21s typically range from 20-30%. Strong preliminary data, clear significance, and demonstrated feasibility are key to competitiveness. New researchers entering the substance use field may have good chances if the science is solid.
💡 Tips for applicants
- Use existing, high-quality datasets: The review committee expects you to leverage publicly available or institutional data (e.g., NIDA datasets, SAMHSA surveys, EHR data). Clearly document data access and availability. This accelerates research pace and demonstrates efficient use of funds.
- Generate strong preliminary data and proof-of-concept: Even though R21 is exploratory, you need to show clear feasibility. Include preliminary analyses, data completeness assessments, and evidence that your research question is answerable with the existing data.
- Be specific about your innovation and significance: Explain why your secondary analysis approach is novel and what gaps in substance use knowledge it will fill. Connect findings to future R01 or clinical translation potential, even though clinical trials aren't allowed in this R21.
- Justify your team composition and timeline: R21s are 2-year projects. Clearly map your specific aims to 24 months. Identify co-investigators with subject matter expertise in substance use research and biostatistics. Justify why existing team capacity is sufficient.
- Address health disparities and implementation relevance: NIH increasingly values research examining disparities in substance use outcomes across racial/ethnic groups, rural vs. urban populations, and socioeconomic strata. Show how your findings will inform real-world prevention or treatment practices.
⚠️ Common mistakes
Applications are often rejected because investigators underestimate the rigor required for secondary data analysis—NIH reviewers expect careful attention to data quality, missing data mechanisms, and statistical validity as if you were analyzing new primary data. Another common pitfall is proposing overly broad aims or trying to answer too many research questions; R21 reviewers prefer tightly focused, clearly scoped projects that can genuinely be completed in two years. Finally, weak or missing preliminary data on data feasibility (e.g., not demonstrating you can actually access the dataset, not showing sample sizes or variable availability) raises serious concerns about project feasibility and leads to low scores.
Similar grants
- OPEN Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed) — National Institutes of Health
- CLOSED Exploratory Clinical Neuroscience Research on Substance Use Disorders — National Institutes of Health
- OPEN Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required) — National Institutes of Health
- OPEN Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required) — National Institutes of Health
- OPEN High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) — National Institutes of Health